secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-05-29T20:05:14+00:00
Accession:  0001193125-26-248242
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia shareholders approve 5.2M-share increase to 2024 equity plan, re-elect three Class I directors
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.
- Re-elected Class I directors James M. Daly, Edmund P. Harrigan, and Adora Ndu to Board until 2029.
- Advisory vote on executive compensation approved with 98.7% of votes cast in favor.
- Ernst & Young ratified as independent auditor for FY2026 with 157,409,378 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/0001193125-26-248242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/d140910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-248242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer